Last reviewed · How we verify
CKD-519
At a glance
| Generic name | CKD-519 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors (PHASE2)
- Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 (PHASE1)
- Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 (PHASE1)
- Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects (PHASE1)
- Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519 (PHASE1)
- Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers (PHASE1)
- Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject. (PHASE1)
- Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-519 CI brief — competitive landscape report
- CKD-519 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI